Tralokinumab Treatment In Patients With Atopic Dermatitis and Moderate-to-Severe Hand Involvement: Results From the 32-week Phase 3b ADHAND Trial. J of Skin. 2026;10(2):s744. doi:10.25251/ppt8ep84